| Literature DB >> 26438785 |
Guri Holmen Gundersen1, Tone M Norekval2, Hilde Haugberg Haug1, Kyrre Skjetne1, Jens Olaf Kleinau1, Torbjorn Graven1, Havard Dalen3.
Abstract
OBJECTIVES: Medical history, physical examination and laboratory testing are not optimal for the assessment of volume status in heart failure (HF) patients. We aimed to study the clinical influence of focused ultrasound of the pleural cavities and inferior vena cava (IVC) performed by specialised nurses to assess volume status in HF patients at an outpatient clinic.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26438785 PMCID: PMC4717409 DOI: 10.1136/heartjnl-2015-307798
Source DB: PubMed Journal: Heart ISSN: 1355-6037 Impact factor: 5.994
Figure 1Flow chart of the study. All participants underwent full cross-over with examinations with and without ultrasound (US) in a random order at every study visit. The sequence was randomised by draw both at first and follow-up study visits. Echocardiography for validation was only performed at first visit (N=62). Both the teams with and without access to US made therapeutic decisions based on all available information (usual care±US examination). N, number of visits; NYHA, New York Heart Association; US(−), without access to ultrasound; US(+), with access to ultrasound.
Clinical characteristics of the 62 study participants
| Mean±SD (range) | |
|---|---|
| Age, years | 74±12 (35–91) |
| Women, n (%)* | 30 (48)* |
| Body mass index (kg/m2) | 28.3±5.5 (18.6–45.8) |
| Systolic blood pressure (mm Hg) | 121±23 (80–171) |
| Diastolic blood pressure (mm Hg) | 71±14 (50–107) |
| Sinus rhythm, n (%)* | 25 (40)* |
| Heart rate, bpm | 79±21 (51–140) |
| NT-proBNP, ng/L | 3761±3072 (90–9999) |
| eGFR, mL/min/1.73 m2 (Cockcroft-Gault) | 34±15 (12–85) |
| NYHA functional class, median (25th and 75th centile)* | II (I and III)* |
| Cause of heart failure; ischaemic, n (%)* | 31 (50)* |
| Cause of heart failure; mainly diastolic, n (%)* | 15 (24)* |
| Using diuretics, n (%)* | 56 (90)* |
| Using β-blockers, n (%)* | 49 (79)* |
| Using ACEI or ARB, n (%)* | 37 (60)* |
| EF (%) | 33.7±13.6 (7–64) |
| LV end-diastolic dimension, mm | 56±11 (22–80) |
| LV end-diastolic volume, mL | 136±76 (35–398) |
| Mitral early inflow, cm/s | 83±25 (39–144) |
| Mitral early inflow deceleration time, ms | 176±47 (82–263) |
| Any pleural effusion, n (%)* | 26 (42)* |
*Data not presented as mean±SD (range), and thus specified.
ACEI, angiotensin-converting enzyme inhibitor; ARB; angiotensin receptor blockers, eGFR; estimated glomerular filtration rate, n; number; NT-proBNP; N-terminal pro-brain natriuretic peptide; NYHA; New York Heart Association.
Agreement of different indices relevant for heart failure assessment in 119 crossover consultations by the two nurses
| Agreed, n (%) | Agreement (r/κ) | |
|---|---|---|
| NYHA class | 97 (82) | 0.67 |
| Peripheral oedema | 88 (74) | 0.59 |
| Volume status | 75 (63) | 0.38 |
| Diuretic treatment* | 88 (74) | 0.46 |
The table shows the fair to substantial agreement between the two nurses of different indices relevant for heart failure assessment (all p<0.001). Volume status assessed by clinical findings, laboratory tests and with or without focused ultrasound examination. Agreed describes the number (%) with exact match, while the agreement by Spearman correlation statistics takes weighted difference into account.
*Agreement is between the two teams (nurse and cardiologist with and without access to ultrasound, respectively).
NYHA, New York Heart Association; r, correlation; κ, kappa statistics.
Figure 2Correlation of ultrasound indices to assess volume status by nurses with reference. The figure shows correlation of: (A) quantification of pleural effusion measured as the dimension of fluid between the diaphragm and the lung surface with patients in sitting position; and (B) end-expiratory dimension of the inferior vena cava (IVC) by pocket-size imaging device (PSID) examinations performed by nurses plotted against similar measurements by reference echocardiography. In (A) no effusion measured by both the nurse and reference is shown as the dot at 0; 0 and the dot at 0.5; 0.5 refers to effusion in the costodiaphragmatic recess only measured by both users.
Predictors of diuretic therapy at first visit and follow-up study visits
| Covariates | First study visit | Follow-up study visits | ||||
|---|---|---|---|---|---|---|
| β | R2 | p Value | β | R2 | p Value | |
| Volume status included US | 0.576 | 37.5 | <0.001 | 0.575 | 39.1 | <0.001 |
| IVC category | 0.290 | 20.7 | <0.001 | 0.139 | 6.2 | <0.001 |
| IVC dimension | 0.263 | 11.5 | 0.01 | 0.302 | 18.6 | <0.001 |
| Pleural effusion | 0.109 | 9.0 | 0.02 | 0.885 | 13.0 | <0.01 |
| Volume status without US | 0.284 | 7.5 | 0.03 | 0.349 | 14.0 | <0.01 |
| Weight | 0.002 | 0.4 | 0.63 | 5.43 | 12.0 | <0.01 |
| Oedema | 0.107 | 2.0 | 0.27 | 0.126 | 2.7 | 0.22 |
| NYHA class | 0.187 | 2.6 | 0.21 | 0.168 | 3.9 | 0.14 |
| Creatinine | −0.001 | 0.5 | 0.60 | −0.430 | 2.0 | 0.29 |
| NT-proBNP | 0.000 | 0.5 | 0.10 | 0.018 | 1.6 | 0.35 |
β coefficients, coefficient of determination (R2) and level of significance assessed in univariate model with ‘Diuretic therapy’ as reduced (−1), unchanged (0) or increased (+1) as dependent variable and the listed covariates. By first study visit (n=62) oedema, NYHA class, weight, creatinine, and NT-proBNP were included as absolute values as described in the Methods section. By follow-up study visits the latter three covariates were included as relative change since last contact, and oedema and NYHA class were included as absolute changes, respectively. Pleural effusion was included as sum of semi-quantitative classification at first contact and as the average change of left and right pleural cavity graded as: −1, reduced measure >1 cm; +1, increased measure >1 cm; or 0 when change was <1 cm.
IVC, inferior vena cava; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; US, ultrasound assessment of the pleural cavities and IVC.